
WM · NYSE
The supplied consensus is Buy across 18 analysts, with a mean price target of $264. The evidence does not provide low or high targets, so target clustering and the width of the spread cannot be established. No firms, individual analysts or target revisions are identified, leaving the most and least bullish analysts undisclosed and preventing a conclusion on the direction of revisions during the week. The substantive disagreement is therefore not attributable to named analysts; the operating debate centers on whether pricing discipline, cost controls and EBITDA growth can offset softer volumes and the uncertain payoff from technology investments and healthcare integration.